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Accepted 4 May 2016In clinical oncology, diagnosis and evaluation of optimal treatment strategies aremostly based on histopatholog-
ical examination combined with immunohistochemical (IHC) expression analysis of cancer-associated antigens
in formalin ﬁxed parafﬁn-embedded (FFPE) tissue biopsies. However, informative IHC analysis depends on both
the speciﬁcity and afﬁnity of the binding reagent, which are inherently difﬁcult to quantify in situ. Here we de-
scribe a label-free method that allows for the direct and real-time assessment of molecular binding kinetics in
situ on FFPE tissue specimens using quartz crystal microbalance (QCM) enabled biosensor technology. We
analysed the interaction between the rVAR2 protein and its placental-like chondroitin sulfate (pl-CS) receptor
in primary human placenta tissue and in breast and prostate tumour specimens in situ. rVAR2 interacted with
FFPE human placenta and cancer tissue with an afﬁnity in the nanomolar range, and showed no detectable inter-
action with pl-CS negative normal tissue.We further validated themethod by including analysis with the andro-
gen receptor N-20 antibody (anti-AR). As the KD value produced by this method is independent of the number of
epitopes available, this readout offers a quantitative and unbiased readout for in situ binding-avidity and amount
of binding epitopes. In summary, thismethod adds a new and important dimension to classical IHC-basedmolec-
ular pathology by adding information about the binding characteristics in biologically relevant conditions. This
can potentially be used to select optimal biologics for diagnostic and for therapeutic applications as well as
guide the development of novel high afﬁnity binding drugs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Malaria1. Introduction
Cancer is a capital health problem in the modern world and there-
fore a major focus of modern medical research. Currently, diagnosis
and disease management of most types of cancer is based onParasitology, Bartholinsgade 2,
Centre, Vancouver, BC V6H 3Z6,
ds.daugaard@ubc.ca
. This is an open access article underhistopathological examination, combined with a molecular pathology
analysis of primary tumour andpotentialmetastatic lesions [3]. Classical
molecular pathology analysis involves IHC evaluation of biomarkers
that can inform on disease status and cancer subtype, as well as onmo-
lecular signatures able to guide therapy. The standard analysis is two-di-
mensional in the sense that the output only informs on expression
intensity and pattern of the biomarker(s) in question.Nevertheless,mo-
lecular pathology assessment plays an important role in the diagnosis
and disease management of several types of cancer. For example, IHC
staining intensity and pattern of ErbB2/HER2 is widely used to guide
treatment in human breast cancer [4,10,30]. In prostate cancer, the ex-
pression intensity and pattern of the androgen receptor (AR) is usedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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formative outcome of any molecular pathology analysis depends solely
on the quality of the binding reagent and the avidity of the ligand-epi-
tope interaction in in situ, which constitutes an inherent limitation of
the method. Investigating the molecular characteristics of the interac-
tion of a given targeting reagentwith a biomarker could add extra infor-
mation that would aid in disease diagnosis, patient stratiﬁcation, aswell
as in evaluation for therapy [11].
Adding to the limited repertoire of informative tumour biomarkers,
we have recently described a distinct chondroitin sulfate (CS) glycos-
aminoglycan (GAG)modiﬁcation shared between theplacental andma-
lignant tissue compartments [27]. The observation was made in our
work with placental malaria, in which infected erythrocytes express
the VAR2CSA protein that allows them to anchor very speciﬁcally to a
distinct type of CS in the placenta, thereby avoiding immune surveil-
lance in the spleen [6,7,28]. Interestingly this distinct type of placen-
tal-like CS (pl-CS) is present on most cancer cells as well, while absent
from normal tissue except placenta. This demonstrates the status of
pl-CS as a cancer speciﬁc oncofetal antigen. pl-CS can be detected in
vitro, in vivo and in situ using recombinant VAR2CSA proteins (rVAR2)
[27]. The pl-CS modiﬁcation is broadly present across multiple tumour
types and the intensity of pl-CS tissue staining correlates with progres-
sion of malignantmelanoma and predicts poor recurrence-free survival
in non-small cell lung cancer patients [27]. Although a promising new
cancer biomarker detection-reagent, rVAR2 is subject to the same limi-
tations of standard molecular pathology analysis as any other
established biomarker reagent, lacking important information on li-
gand-epitope binding avidity.
The Attana biosensor is an acoustic biosensor thatmeasures changes
in mass using the piezoelectric capacity of a quartz crystal (QCM tech-
nology) [17]. The change in mass per unit area on the crystal is directly
proportional to the change in the crystals resonant frequency [29]. This
allows for the use of the QCM technology as a microscale to measure
small changes in mass, such as binding of an analyte to its immobilized
ligand. More importantly, unlike surface plasmon resonance (SPR,
Biacore [25,33]), which relies on the reﬂection of polarized light, the
QCM platform is independent of the composition of the immobilized li-
gand. This technology therefore allows for the characterization of the
binding and kinetic properties of a given analyte's interaction with a li-
gand in its native environment using ﬁxed cells [18,23,24], and recently
also live cells [16]. However, to date this has not been attempted for in
situ FFPE tissue analysis of primary patient biopsies. Here, we present
a method that adds a third dimension to classical two-dimensional mo-
lecular pathology assessment by incorporating a kinetic readout of ana-
lyte-ligand interactions in situ using QCM biosensor technology.
2. Materials and methods
2.1. Materials and reagents
Antibodies used for immunohistochemistry (IHC) and immunoﬂuo-
rescence (IF) were anti-AR rabbit polyclonal antibody (1:200, N-20,
Santa Cruz, sc-816), anti-V5-FITC antibody (1:500, Life Technologies,
46–0308) and ﬂuorescein anti-rabbit IgG antibody (1:500, Vector Labo-
ratories, FI-1000).
2.2. Immunohistochemistry
Tissue stainings were performed using the Ventana Discovery plat-
form. Sectioned parafﬁn embedded tissue samples were deparafﬁnized
in EZ prep solution (Ventana) and stained with V5-tagged rVAR2 or
anti-AR (N-20, Santa Cruz) antibody. In brief, tissue sections were incu-
bated in Cell Conditioning 1 (CC1) or Cell Conditioning 2 (CC2) solution
(Ventana) to retrieve antigen, followed by incubation with primary
staining molecules. Bound rVAR2 was detected with an anti-V5 anti-
body, and an anti-mouse-HRP detection step. Bound antibodies wereincubated with universal secondary antibody and visualized using
Streptavidin-biotin peroxidase detection system and 3.3′-diaminoben-
zidine as chromogen.2.3. Tissue immobilization
Attana COP-1 cartridges were disassembled to retrieve the COP-1
gold chip. The chip was coated in poly-L-lysine solution 5min at RT
(Sigma) prior to tissue immobilization. The chip was rinsed in PBST
and allowed to dry at RT for 2h. The FFPE tissue, tested positive for the
given target in IHC, was macro-dissected at 5μm thickness on a micro-
tome. The tissue was mounted on the chip and baked at 60°C for 1h.2.4. Chip deparafﬁnization and antigen retrieval
The tissue chips were deparafﬁnized in EZ prep solution at 65°C in a
water bath for 30min, and rinsed three times in PBS. Antigen retrieval
was performed in 10mM sodium citrate, 0.05% Tween, pH 6 for 30min
at 95°C. The chip was again rinsed three times in PBS. For AR experi-
ments, the tissue was permeabilized in 0.5% saponin in PBS 10min at
RT. For antibody experiments the chips were blocked in 1% BSA, 10%
FBS in PBS for 1 h at RT. For rVAR2 experiments, the chips were blocked
in Synblock (Immunochemistry Technologies) solution for 1h at RT. The
treated tissue chips were mounted in the COP-1 cartridges, being very
careful not to allow leakage of ﬂuid to under the chip. In the optimiza-
tion step the tissue was stained with ethidium bromide, and the integ-
rity of the tissue was viewed in a top-down ﬂuorescence microscope.2.5. Cell chip preparation
Cells were seeded on COP-1 surfaces (Attana AB) at 80.000 cells in
700 uL of appropriate supplemented growthmedia. Following a 24h in-
cubation at 37°C, 5% CO2, the cells were ﬁxed 10min in 4% PFA in PBS.
The cells were washed in PBS and the cartridge was assembled, being
careful of leakage. In the optimization step the cells were stained with
ethidium bromide, and viewed in a top-down ﬂuorescence microscope.2.6. Puriﬁcation of pl-CS from human placenta
5g of frozen placental tissue was minced and extensively washed
with cold PBS. The tissue was then treated with 10mg collagenase
type IV (Life Technologies) in 10mL PBS containing Ca2+ and Mg2+,
for 16h at 37°C. The resulting supernatant was cleared at 3000g for
10min. The pellet was further digested with Trypsin EDTA (Lonza) for
2h at 37°C. The resulting supernatant was cleared at 3000g for 10min.
All the supernatants were combined and lyophilized. The dried extract
was delipidated using a series of chloroform and methanol washes
using 2:1, 1:1, 1:2 v/v ratios and dried at 55°C. The sample was then
digested with 20mg Pronase (Roche) in 20mL 50mM Tris/HCl, pH7
and 5mM CaCl2 for 16h at 50°C. After heat inactivation of the Pronase,
2mM MgCl2 and 1000U Benzonase (Sigma-Aldrich) were added and
the sample was incubated for 2h at 37°C. The sample was run on a
DEAE column and eluded in 20mM NaOAc, pH 6, 1 M NaCl. The GAGs
were precipitated in 3 volumes on ethanol 24h at 4°C. The precipitate
was collected at 9000g for 30min and dried at 50°C. The dried sample
was then resuspended in water and desalted using a PD-10 column
(GE Healthcare). The sample was then treated with hyaluronidase
from Streptomyces hyalurolyticus (Seikagaku Biobusiness Corporation,
Japan), and A mixture of Flavobacterium heparinum heparin lyase I, II,
and III in succession. The chondroitin sulfate was then precipitated in
three volumes of ethanol, dried, and resuspended in water. The struc-
ture, purity and concentration was determined by MS.
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Puriﬁed CS from the placenta was modiﬁed with an activated biotin
reagent (sulfo-NHS-LC-biotin, Thermo-Pierce, Rockford, IL) at the
amine group of the residual peptide left at the reducing end of CS
chain after the trypsin digestion puriﬁcation step. In Short the placental
CS-peptide (100μg) in 50μL of 50mM phosphate buffer, pH 7.4, was
mixed with the biotin reagent (1.0μmol) and incubated at room tem-
perature for 2h. 5μL of 1M ethanolamine was then added to the mix
and incubated at room temperature for 20min to terminate the reaction.
The biotin-modiﬁed placental CS was puriﬁed on a Superose 12 HR 10/
300 column (GE Healthcare, Piscataway, NJ) using 0.2M ammonium ac-
etate as the eluent. The eluted product was ﬁnally freeze-dried three
times. The placental CS-Biotin powder was resuspended in H2O prior
to use in experiments.
For immobilization of the puriﬁed biotinylated pl-CS on Biotin Chips
a biotin chip (Attana AB) was allowed to stabilize in 10mM HEPES,
150mM NaCl, 0.005% Tween-20 at a ﬂow rate of 100μL/min on the
Attana Cell™ 200 instrument. The ﬂow rate was lowered to 20μL/min
and 100μg/mL streptavidin (Attana AB) was injected and allowed to in-
teract with the surface. The pl-CS-biotin was then diluted to 50μg/ml
and injected on the surface for immobilization.
2.8. Kinetic analysis
The chips were inserted in the Attana Cell 200 instrument (Attana
AB) and allowed to stabilize in running buffer at 25μL/min (10μL/min
for the AR experiments). The puriﬁed pl-CS experiment and tests of
monoclonal antibodies were run in PBS. rVAR2 cell and tissue experi-
ments were run in PBS containing Synblock diluted to 0.1× stock solu-
tion (Immunochemistry Technologies). Once stable, the baseline was
veriﬁed with repeated injections of running buffer. The analyte to be
tested was dissolved in the appropriate running buffer and diluted
two-fold to yield the given concentration range. All injectionswere per-
formed by the C-Fast autosampler (Attana AB). Baseline was checked
between sample injections, by injections with running buffer. Blank in-
jectionswere subtracted from the sample injections in theﬁnal analysis.
The analytes were tested for reactivity against blank surfaces and
against the given negative controls. The data was prepared using the
Attana Attache software (Attana AB) and curve ﬁtting was performed
in the TraceDrawer software (Ridgeview Instruments) using the ﬁt
models given in Table 1. For some experiments a low level of back-
ground binding was accounted for by ﬁtting a 1:2 model. Only the
true high afﬁnity values (KD values) are listed in Table 1. For CSA inhibi-
tion, rVAR2 at a concentration of 100nMwas pre-incubatedwith 400μg/
mL bovine CSA (Sigma) and injected over the surface. For the veriﬁca-
tion of tissue adherence, rVAR2 was injected over the tissue surface
until saturation. The lid on the COP-1 Cartridge was removed and the
tissue incubated 30min with anti-V5-FITC (Invitrogen) at RT. The chip
was washed and viewed under a top-down ﬂuorescence microscope.Table 1
Curve ﬁtting data for all QCM experiments. Listed is the tested analyte, the immobilized ligand,
estimated error in that particular ﬁt. NA depicts experiments forwhich no kineticﬁt could be ob
Sample Fit model Ka (1/M
rVAR2 Placental tissue 1:2 9.2 × 1
Prostate cancer tissue 1:1 12.7 ×
Tonsil tissue NA NA
Breast cancer tissue 1:2 7.9 × 1
Puriﬁed placental CS 1:1 12.3 ×
LNCap cells 1:2 9.4 × 1
SKBR3 cells 1:2 6.8 × 1
CHO-s745A cells NA NA
αAR Prostate cancer tissue 1:2 13.0 ×
Placental tissue NA NA
LNCap cells 1:2 7.4 × 1
PC3 cells 1:2 23.7 ×2.9. Immunoﬂuorescence
The given cancer cell lines were seeded at a subconﬂuent concentra-
tion on glass slides and allowed to adhere at 37°C, 5% CO2. The cells were
then ﬁxed in 4% PFA andwashed in PBS. The cells were blocked for 1h at
RT in 1% BSA, 5% FBS in PBS. The cells were then stained with V5 tagged
rVAR2 or anti-AR (N-20, Santa Cruz) for 1h at RT in PBS containing 0.25%
BSA. The cells were washed and incubated with anti-V5-FITC or anti-
mouse-FITC in PBS containing 0.25% BSA. The slides were stained with
DAPI, mounted, and viewed using confocal microscopy.
For the measurement of ﬂuorescence intensity in the Attana chip
rVAR2 detection on the prostate and tonsil tissues, 7 distinct areas of
the tissue were selected and quantiﬁcated using the ImageJ software.
Data is presented as Corrected Total Tissue Fluorescence (CTTF), for
which the following formula was used, as described before: CTTF = In-
tegrated density− (Area of selected region ×Mean ﬂuorescence of the
background) [2,20]. Quantiﬁcation shown represents one measured
experiment.
2.10. Microscospy
A Nikon C1 confocal microscope with a 60× oil objective was used
for imaging the IF cell stainings. A total of 5 representative pictures
were taken per sample. Stainings were repeated twice. For analysis of
the integrity of the immobilized tissue, a Leica DMLB with a Rolera-rx
Fast 1394 camera and a 20× objective was used.
3. Results
3.1. Preparation of FFPE tissue specimens on QCM biosensor chips
Chips for the Attana QCM biosensor come with a wide variety of sur-
faces for the immobilization of different ligands to be analysed. Tradition-
ally the kinetics of biomolecule interactions was studied with puriﬁed
ligand immobilized on polystyrene or covalently linked through primary
amines to reactive surfaces [22]. Recently, cells were grown on polysty-
rene chips optimized for cellular adherence (COP-1) and either ﬁxed to
the surface using PFA [8,23] or tested as live cells [16]. Our aimwas to im-
mobilize a piece of FFPE primary human tissue to the chip for subsequent
binding analysis. The cell COP-1 chips are plasma-treated to become hy-
drophilic, which is optimal for cellular adherence. We macro-dissected a
small circular piece of placental tissue, at a thickness of 5 μmandplaced it
in the middle of a COP-1 surface that was covered with Poly-L-Lysine
prior to tissue immobilization (Fig. 1a).
The detection of protein targets in FFPE tissue requires removal of the
parafﬁn matrix and often requires further treatment for the regeneration
and availability of the target antigens. We performed deparafﬁnization in
EZprep solution and antigen retrieval in 10mM sodium citrate, 0.05%
tween, pH 6 [27]. The chipswere visually inspected at each step to ensure
the presence of the tissue on the chip.themodel used for curve ﬁtting in TraceDrawer, the obtained ka, kd, and KD values, and the
tained due to no analyte binding. These are representative experiments of repeated setups.
∗s) Kd (1/s) KD (nM) Est. Error (nM)
04 3.9 × 10−4 4.3 ±0.01
104 11.3 × 10−4 8.9 ±0.06
NA NA NA
04 5.3 × 10−4 6.7 ±0.3
104 4.42 × 10−4 3.6 0.05
04 5.2 × 10−4 5.5 ±0.0004
04 10.5 × 10−4 15.6 ±0.2
NA NA NA
104 13.1 × 10−4 10 ±0.04
NA NA NA
04 14.0 × 10−4 18.9 ±0.07
104 55.5 × 10−4 23.5 ±0.6
Fig. 1.Tissue immobilization, treatment, and initial test of rVAR2 binding. A) placental tissue tested positive for the presenceof pl-CS using rVAR2 in IHCwas cut and immobilized ona COP-
1 chip. Both H&E staining and rVAR2 staining of matched tissue is shown B) Following tissue immobilization and treatment the placental tissue was tested for the interaction with rVAR2
(1:1 dilution 200nM–3.125 nM) in an Attana Cell 200 instrument. Curve ﬁtting was performed in TraceDrawer. Black curve is original data, red is ﬁtted data. The KD value is listed. Tissue
integrity was visualized with nuclear ethidium bromide staining before and after the experiment. C) rVAR2 was injected over an immobilized piece of placental tissue with and without
pre-incubation with 400μg/mL soluble bovine CSA.
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sue we performed a binding experiment using a titration of rVAR2 pro-
tein (Fig. 1b). The integrity of the tissue was conﬁrmed by visualizing
the tissue with ethidium bromide DNA staining, before and after the
binding experiment. rVAR2 highly interacted with the tissue with a KD
value of 4.3 nM. Furthermore, the interaction was CSA speciﬁc, as
shown by the efﬁcacy of inhibiting rVAR2 adhesion to the placental tis-
sue with soluble CSA (Fig. 1c).
3.2. Afﬁnity of the rVAR2:pl-CS interaction in primary tissue
We have shown that rVAR2 speciﬁcally interacts with pl-CS in the
placenta and in most cancers, without binding CS on normal tissue
[27]. This observation was mainly based on staining FFPE tissues with
rVAR2 in IHC. We wanted to study the kinetics of the interactions and
the relative abundance of pl-CS in patient-derived FFPE primary cancer
tissue. For this purpose, we immobilized FFPE tissue from a prostate
cancer and a breast cancer patient on COP-1 chips, and performed bind-
ing analysis with a titration of rVAR2 (Fig. 2a). A piece of tonsil tissue
was used as the control for normal tissue. rVAR2 interacted to a high de-
gree with both the prostate and breast cancer tissue with comparable
KD values (8.9 nM and 6.7 nM, respectively). As previously observed
[27], rVAR2 staining of the tonsil tissue in IHC was very weak, with
only a limited amount of focal staining (Fig. 2a). In accordance with
this rVAR2 did not interact with the tonsil tissue immobilized on thechip, in real time. To conﬁrm these results and verify that rVAR2
interacted with the tissue, we disassembled the prostate cancer and
tonsil chips following an experiment and conﬁrmed the presence and
localization of rVAR2 binding using an anti-V5-FITC antibody (Fig. 2b
and c). This showed an intense staining of the prostate cancer tissue
with very limited signal seen on the tonsil chip.
To date, biosensor analysis has relied on the interaction between an
analyte and an immobilized cell or puriﬁed receptor [5,8,16,22,23]. In
line with this, we have previously investigated the interaction between
several recombinant VAR2CSA proteins and immobilized bovine
decorin [6,7], as well as the interaction of rVAR2 with a melanoma cell
[27]. To verify the interaction between rVAR2 and the immobilized tis-
sue, we performed the same analysis on puriﬁed placental-like CS and
cancer cells of prostate and breast cancer origin (Fig. 3). We puriﬁed
pl-CS from placenta, biotinylated it through the peptide remaining
from protease treatment, and immobilized it on an Attana biotin chip.
Aswith the tissue, rVAR2 interacted highlywith the pl-CS on the surface
in the same concentration range and with a comparable KD value
(3.6nM) (Fig. 3a). To further verify the interaction we cultured an AR
positive prostate cancer cell line (LNCap), and a breast cancer cell line
(SKBR3) on the surface of a COP-1 chip,ﬁxed them in PFA, and subjected
them to the same analysis. Both cell lines were shown positive for the
presence of pl-CS by rVAR2 staining in IF (Fig. 3b). The interaction anal-
ysis was comparable between the two cells lines and the analysis per-
formed on the tissues and the puriﬁed pl-CS (Fig. 3b). A CHO cell
Fig. 2. Investigating the interaction between rVAR2 and pl-CS in cancer Tissue. A) Prostate cancer, breast cancer, and tonsil tissue were stained with rVAR2 in IHC. Both H&E staining and
rVAR2 staining ofmatched tissue is shown.Matched tissuewas immobilized on COP-1 surfaces and subjected to binding analysiswith rVAR2 (1:1 dilution 200 nM–3.125 nM) in anAttana
Cell 200 instrument. Curve ﬁtting was performed in TraceDrawer. Black curve is original data, red is ﬁtted data. The KD value is listed. B) To further test the interaction a piece of prostate
cancer or tonsil tissue, immobilized on a COP-1 chip, were saturatedwith rVAR2 in an Attana Cell 200 instrument. The chips were disassembled and the presence of v5 tagged rVAR2 was
visualized with anti-V5-FITC. C) Quantiﬁcation of ﬂuorescence from 10 pictures taken of the chips in B).
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low overall glycosaminoglycan (GAG) content, was used as the negative
control for binding. This cell linewas shownnegative for the presence of
pl-CS in IF, and was negative for the interaction with rVAR2 in the bio-
sensor setup (Fig. 3b).
3.3. Afﬁnity of an anti-AR antibody to prostate cancer tissue
To further extend the validation of the tissue biosensor setup, we se-
lected a well-characterized cancer marker for which a validated mono-
clonal antibody is available. We analysed the interaction of the anti-
Androgen Receptor (AR) N-20 antibody, used in the characterization
of prostate cancer [13], with endogenous AR in cancer cells and in
FFPE prostate cancer tissue. LNCap cells are known to express high
levels of AR [21]. In accordance with this the LNCap cells was stained
by anti-AR in IF and the anti-AR antibody interacted with the LNCap
cells immobilized on a COP-1 surface, with a KD value of 18.9 nM (Fig.
4a). Contrary to this PC3 cells, which are known to be androgenindependent [32], showed very little AR staining in IF and a correspond-
ing low level of interaction with the AR-antibody when immobilized on
the biosensor chip (Fig. 4a). Having shown that the antibody worked in
the biosensor setup, we selected an AR positive FFPE primary prostate
cancer tissue biopsy, immobilized it on a COP-1 surface, and performed
binding analysis on the Attana Cell 200. As with the rVAR2 analysis, in-
teraction to the tissue was comparable to that of the immobilized AR
positive cells (KD value of 10 nM) (Fig. 4b). A piece of AR negative pla-
cental tissue showed no interaction with the AR antibody (Fig. 4c),
conﬁrming the target speciﬁcity. When comparing the peak responses
measured in Hz between rVAR2 and anti-AR binding to the primary tis-
sues it is evident that rVAR2 binding is up to 10 fold higher than the
with the antibody.
4. Discussion
Discovery and characterization of cancer-associated markers effec-
tive in cancer diagnosis and treatment is a main focus in modern
Fig. 3. Testing the interaction of rVAR2with puriﬁed pl-CS and ﬁxed cancer cell lines. A) pl-CSwas puriﬁed from human placental tissue, biotinylated, and immobilized on an Attana biotin
chip, and subjected to binding analysis with rVAR2 (1:1 dilution 200 nM–3.125 nM) in an Attana Cell 200 instrument. Curve ﬁtting was performed in TraceDrawer. Black curve is original
data, red is ﬁtted data. The KD value is listed. B) LNCap, SKBR3 and CHO-A745 cells were stained for pl-CS using V5 tagged rVAR2 in IF. The cells were then ﬁxed on Attana COP-1 chips and
subjected to binding analysiswith rVAR2 (1:1 dilution 200 nM–3.125 nM) in anAttana Cell 200 instrument. Curve ﬁttingwas performed in TraceDrawer. Black curve is original data, red is
ﬁtted data. The KD value is listed.
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recently showed that the malarial VAR2CSA protein targets a speciﬁc
type of placental-like chondroitin sulfate found in the placenta and on
most cancer cells [27]. The ﬁeld of medical science increasingly recog-
nizes that a thorough molecular analysis of the biomarker recognition
event is needed for full evaluation of a target for diagnostic and treat-
ment purposes [11]. Such thorough analysis requires an in depth under-
standing of the molecular mechanism underlying the speciﬁc
interaction as well as its kinetic properties. For this purpose scientists
are utilizing a wide range of techniques including nuclear magnetic res-
onance (NMR) [12,26], mass-spectrometry (MS) [12], Enzyme-linked-
immunosorbent-assay (ELISA), isothermal titration calorimetry (ITC)
[15], and biosensor technology [1,5,19,22,24,31]. Common for these
techniques is a requirement for the isolation and puriﬁcation or recom-
binant expression of the targetmolecule.While thesemethods are valu-
able in describing a given biomarker and how to target it effectively,
biomarker extraction is laborious and may interrupt key features only
present in the biomarker's, or target's, native environment.
Current molecular pathology relies on the intensity and pattern of
expression of the given biomarker using two-dimensional histopatho-
logical and IHC analysis. This work aims at adding an extra dimension
of interaction time to classic pathology by performing kinetics of bind-
ing analysis directly on FFPE primary tissue specimens. We believe
that this provides pathologists with a tool to evaluate disease speciﬁc
targets not only by their presence and speciﬁc localization, but also by
their molecular characteristics and how this relates to its direct interac-
tion with a targeting molecule.Wemacro-dissected out a small circular piece of parafﬁn-embedded
tissue and put it on COP-1 Attana QCM chip surfaces. We then removed
the parafﬁn and performed antigen retrieval. One problemwas that the
tissue did not stick sufﬁciently to non-treated COP-1 surfaces. A coating
with poly-L-lysine was needed for proper immobilization. The antigen
retrieval needed was optimized by IHC staining using the analytes in
question. Subsequently, the tissue-coated chipswere treated in an iden-
tical way, allowing for direct comparison. Since no light can go through
the gold COP-1 surface, we visualized the immobilized tissue by a DNA
stain and a ﬂuorescent microscope before and after the experiments to
ensure the integrity of the tissue. No change in morphology was seen,
showing that the proposed method maintains proper tissue integrity
for subsequent analysis. The exact epitope of recognition of the anti-
AR (N-20) antibody and its molecular nature is not known. It is likely
that antibody speciﬁc optimization on tissue treatments is needed to ac-
commodate analysis of other antibodies, such as antibodies targeting
conformational epitopes.
Having optimized the immobilization of the FFPE tissue, we per-
formed binding experiments using rVAR2 and Anti-AR (N-20)monoclo-
nal antibodies on tissues veriﬁed for the presence of the target antigen
in question. All binding experiments were veriﬁed against appropriate
cell lines, and in the case of rVAR2 also puriﬁed pl-CS. rVAR2 showed
similar binding kinetics to puriﬁed placental-like CS, cell lines, and tis-
sue. This conﬁrms our strategy and supports the use of primary tissue
for QCM experiments. It is common to evaluate speciﬁc binding in bio-
sensor experiments by subtracting binding to a blank reference [25].
However, in working with immobilized cells and tissues we found
Fig. 4. Investigating the Interaction between clinically relevantmonoclonal antibodies and their targets in Cancer Tissue. A) LNCap and PC3 cells were tested for the expression of AR by IF.
The cells were ﬁxed to an Attana COP-1 surface. The chips were then subjected to binding analysis with anti-AR (N-20, Santa Cruz) (1:1 dilution 200 nM–3.125 nM) in an Attana Cell 200
instrument. Curve ﬁttingwas performed in TraceDrawer. Black curve is original data, red isﬁtted data. The KD values are listed. B) A piece of primary prostate cancer tissuewas selected for
high AR expression in IHC, and a matched piece of tissue was immobilized on a COP-1 surface. Kinetic analysis was performed as in A. C) A piece of primary placental tissue was
immobilized on a COP-1 surface and subjected to kinetic analysis as in A. Curve ﬁtting was not possible due to no binding.
29T.M. Clausen et al. / Sensing and Bio-Sensing Research 9 (2016) 23–30that binding of an analyte to a blank chip is not representative of the
background seen in binding to a chip coated with cells or tissues.
When investigating the interaction between an analyte and a puriﬁed
receptor in classic SPR, the surface area available for non-speciﬁc inter-
actions on the chip can be considered comparable. This is not the case
when investigating a chip covered in tissue or cells. Subtracting the sig-
nal from the reference chip therefore introduced a negative bias on the
‘true’ interaction, visualized as a negative spike in the real-timeobservation of the on-rate (Data not shown). Instead we selected cells
and tissues negative for the ligand in question as proper negative con-
trols, and presented them as separate ﬁgures to demonstrate the back-
ground independently. In this, rVAR2 did not interact with normal
tissue (tonsil), conﬁrming our previous observations that rVAR2 stain-
ing is placenta and cancer speciﬁc [27]. Furthermore, rVAR2 did not in-
teract with the CS negative CHO-A475a cells and binding could be
inhibited with soluble CSA, conﬁrming the CS speciﬁcity. The analysis
30 T.M. Clausen et al. / Sensing and Bio-Sensing Research 9 (2016) 23–30of the AR interaction showed the same correspondencewith AR expres-
sion in both cell line and tissue setups. It is notable that such analysis
was possible using a nuclear target.
Interestingly the data shows that pl-CS is abundantly present in tu-
mour tissue compared to AR. This is evident from the high difference
in max binding responses, with the Bmax response for rVAR2 being
up to 10 times higher. This difference is not obvious in the IF staining
and IHC which with the inherent enzymatic horseradish peroxidase
staining is difﬁcult to accurately quantify. The concept of target quantity
is interesting for cancer therapy as targeting an abundant target may
offer a more efﬁcient anti-cancer effect.
We demonstrate that this novel method can be broadly used to de-
termine the relative presence of a cancer speciﬁc target aswell as the af-
ﬁnity of the targeting reagent for its receptor. Implementation of the
method has the potential to inform cancer diagnostics aswell as provide
an important tool for screening of high afﬁnity targeting reagents in
drug development, and aid in patient stratiﬁcation, companion diagnos-
tics and dosage determination during therapeutic treatment.
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